IMNN-101
- Generic Name
- IMNN-101
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Imunon
- Target Recruit Count
- 74
- Registration Number
- NCT06283459
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸DM Clinical Research, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath